{"id":997598,"date":"2026-08-24T12:15:35","date_gmt":"2026-08-24T16:15:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/"},"modified":"2026-08-24T12:15:35","modified_gmt":"2026-08-24T16:15:35","slug":"sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/","title":{"rendered":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT"},"content":{"rendered":"

<\/p>\n

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT<\/p>\n

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE<\/a>)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti<\/a>, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Sarepta Therapeutics<\/a>, Inc. (NasdaqGS: SRPT) (\u201cSarepta\u201d or the \u201cCompany\u201d).<\/p>\n

Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.<\/p>\n

On March 18, 2025, the Company issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with Sarepta’s gene therapy, ELEVIDYS. However, the Company assured investors that “the benefit-risk of ELEVIDYS remains positive.” Then, on June 15, 2025, the Company announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. Finally, on July 17, 2025, the Company revealed that a third patient treated with one of Sarepta’s investigational treatments related to Elevidys had died from acute liver failure in June 2025.<\/p>\n

Thereafter, the Company<\/a> and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.<\/p>\n

KSF\u2019s investigation is focusing on whether Sarepta\u2019s officers and\/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.<\/p>\n

If you have information that would assist KSF in its investigation, or have been a long-term holder of Sarepta shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com<\/a>), or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-srpt\/<\/a> to learn more.<\/p>\n

About Kahn Swick & Foti, LLC<\/p>\n

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation\u2019s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.<\/p>\n

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services<\/p>\n

To learn more about KSF, you may visit www.ksfcounsel.com<\/a>.<\/p>\n

CONNECT WITH US: Facebook<\/a> || Instagram<\/a> || YouTube<\/a> || TikTok<\/a> || LinkedIn<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260824327976\/en\/<\/a><\/span><\/p>\n

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com<\/span><\/a>
1-833-538-3606
1100 Poydras St., Suite 960
New Orleans, LA 70163<\/p>\n

KEYWORDS:<\/b> Louisiana New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (\u201cSarepta\u201d or the \u201cCompany\u201d). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. On March 18, 2025, the … <\/p>\n

Continue reading “Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-997598","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (\u201cSarepta\u201d or the \u201cCompany\u201d). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. On March 18, 2025, the … Continue reading "Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T16:15:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT\",\"datePublished\":\"2026-08-24T16:15:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/\"},\"wordCount\":547,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/\",\"name\":\"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-24T16:15:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk","og_description":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (\u201cSarepta\u201d or the \u201cCompany\u201d). Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. On March 18, 2025, the … Continue reading \"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-24T16:15:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT","datePublished":"2026-08-24T16:15:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/"},"wordCount":547,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/","name":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-24T16:15:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260824327976r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-sarepta-therapeutics-inc-srpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. – SRPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=997598"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=997598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=997598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=997598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}